A Phase 2/3 interventional study of AG-236 and Placebo in Polycythemia Vera, sponsored by Agios Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236 works compared to placebo to increase the number of subjects with no phlebotomy and absence of phlebotomy eligibility over a 13-week period. In addition, the long-term effect of AG-236 on efficacy and safety will be explored in an open-label extension portion.
AG-236 is a small interfering ribonucleic acid (siRNA) targeting transmembrane serine protease 6 (TMPRSS6) intended for the treatment of PV. The study aims to evaluate the efficacy and safety of treatment with AG-236 in subjects with PV. The study is a Phase 2/3 study in which the recommended dose and dose regimen of AG-236 will be selected and further evaluated. The Phase 2 portion includes a 26-week randomized, placebo-controlled period in which subjects will be randomized in a 1:1:1:1:1 ratio to receive 1 of 3 dose levels of AG-236 in 1 of 2 dose regimens or placebo. The Phase 3 portion includes a 26-week randomized, placebo-controlled period in which subjects will be randomized in a 2:1 ratio to receive the recommended AG-236 dose level and dose regimen or placebo. Subjects who complete either the Phase 2 or Phase 3 portion will have the option to move into a 104-week open-label extension period to receive AG-236.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
This study's planned enrollment of 245 is above the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Browse Polycythemia Vera studies →Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Key Inclusion Criteria:
Phlebotomy requirements:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive AG-236 Dose X, administered subcutaneously (SC), according to the assigned dosing regimen, along with placebo administered SC as needed to maintain the blind in the double-blind period and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.
Drug: AG-236 · Drug: Placebo
Subjects will receive AG-236 Dose Y, administered SC, according to the assigned dosing regimen, along with placebo administered SC as needed to maintain the blind in the double-blind period and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.
Drug: AG-236 · Drug: Placebo
Subjects will receive AG-236 Dose Z, administered SC, according to the assigned dosing regimen, along with placebo administered SC as needed to maintain the blind in the double-blind period and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.
Drug: AG-236 · Drug: Placebo
Subjects will receive AG-236 Dose ZZ, administered SC, according to the assigned dosing regimen in the double-blind period, and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.
Drug: AG-236
Subjects will receive placebo administered SC, according to the assigned dosing regimen in the double-blind period and will be randomized to receive AG-236 Dose X, Y, or Z if they opt to participate in the extension period.
Drug: Placebo
Subjects will receive AG-236, administered SC at the dose and dose regimen selected for Phase 3 for 26 weeks in the double-blind period. Subjects who complete the double-blind period of the study will be eligible to continue receiving AG-236 in the open-label extension period.
Drug: AG-236
Subjects will receive placebo administered SC at the dose and dose regimen selected for Phase 3 for 26 weeks in the double-blind period. Subjects who complete the double-blind period of the study will be eligible to continue receiving AG-236 in the open-label extension period.
Drug: Placebo
SC Injection
SC Injection
Phase 2 and Phase 3: Percentage of Subjects With No Phlebotomy and Absence of Phlebotomy Eligibility
Time frame: Week 13 Through Week 26
Phase 2 and Phase 3: Number of Phlebotomies During the Double-blind Period
Time frame: Up to Week 26
Phase 2: Percentage of Subjects Achieving Hematocrit (HCT) Response During the Double-blind Period
HCT response is defined as having at most one HCT assessment ≥45 percent (%) during the double-blind period.
Time frame: Up to Week 26
Phase 2 and Phase 3: Time to First HCT ≥45%
Time frame: Up to Week 26
Phase 2 and Phase 3: Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to Week 130
Phase 2 and Phase 3: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Maximum Observed Plasma Concentration (Cmax) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Percentage of Area Under the Concentration-Time Curve due to Extrapolation From the Last Quantifiable Concentration to Infinity (AUC%extrap) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Time to Last Measurable Concentration (tlast) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Time to Reach Maximum Observed Plasma Concentration (tmax) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Terminal Elimination Half-Life (t1/2) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Apparent Total Body Clearance (CL/F) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 2 and Phase 3: Apparent Volume of Distribution (Vz/F) of AG-236
Time frame: Each dose occasion from Day 1 to Week 52
Phase 3: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 8a T-score at Week 26
Time frame: Baseline, Week 26
Phase 3: Change From Baseline in PROMIS Fatigue SF 8a T-score at Week 26 Among Those who Have Fatigue at Baseline
Time frame: Baseline, Week 26
Phase 3: Percentage of Subjects With Improvement in the Patient Global Impression of Severity (PGIS) -Fatigue by at Least one Category at Week 26 Compared with Baseline or "No Change" if None or Mild Fatigue at Baseline
Time frame: Baseline, Week 26
Phase 3: Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) -Fatigue at Week 26 or "No Change" if None or Mild Fatigue at Baseline
Time frame: Baseline, Week 26
Phase 3: Change From Baseline in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 Total Symptom Score at Week 26
Time frame: Baseline, Week 26
Phase 3: Change From Baseline in MFSAF v4.0 Total Symptom Score at Week 26 Among Those who Have Symptoms at Baseline
Time frame: Baseline, Week 26
Phase 3: Percentage of Subjects With Improvement in the PGIS-PV Symptoms by at Least 1 Category at Week 26 Compared With Baseline or "No Change" if None or Mild PV Symptoms at Baseline
Time frame: Baseline, Week 26
Phase 3: Percentage of Subjects With Improvement in the PGIC-PV Symptoms at Week 26 or "No Change" if None or Mild PV Symptoms at Baseline
Time frame: Baseline, Week 26
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Aug 2030, 45 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.